Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 genetic mutations. This trial compares bilateral salpingectomy, which removes only the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The goal is to find out if removing just the fallopian tubes with delayed ovary removal is nearly as effective as removing both from the start. Participants choose between two groups one undergoes bilateral salpingectomy with the option of later ovary removal, and the other undergoes bilateral salpingo-oophorectomy. Both groups have imaging tests like pelvic ultrasounds or pelvic MRIs during screening and provide blood samples throughout the study. Follow-up visits occur at multiple time points, including 10 to 60 days, 6 months, 12 months, 24 months, and then yearly for up to 20 years. During the study, researchers track if ovarian or related cancers develop and assess symptoms related to estrogen loss, quality of life, cancer-related distress, sexual function, menopausal symptoms, medical decision making, and any adverse events. Various questionnaires and imaging tests support these evaluations. Long-term safety and cancer risk reduction are monitored for up to two decades after surgery.
Actively Recruiting
Researchers are evaluating the drug TNX-102 SL to see if it helps treat adults with moderate to severe major depressive disorder MDD. This study aims to compare TNX-102 SL with a placebo to determine its effect on depression symptoms using a rating scale, and to assess the safety and medical issues participants may experience while taking the drug. Participants will take either 5.6 mg of TNX-102 SL two 2.8 mg tablets or matching placebo tablets every night at bedtime for six weeks. During the study, participants will visit the clinic every two weeks for checkups and tests to monitor their progress. Throughout the study, researchers will assess changes in depression severity using the MADRS score and other measures such as sleep disturbance and clinical impression scales. Safety and tolerability will also be monitored. Participation involves regular clinic visits over the six-week treatment period, with assessments occurring at baseline and every two weeks until the study concludes.
Actively Recruiting
Researchers are evaluating whether adding surgery to remove the kidney cytoreductive nephrectomy improves overall survival compared to immunotherapy-based drug combinations alone in patients with metastatic kidney cancer. This phase III trial focuses on patients with newly diagnosed metastatic renal cell carcinoma, exploring the effects of combining surgery with immunotherapies such as nivolumab, ipilimumab, pembrolizumab, and avelumab, along with axitinib, which may help slow tumor growth. Participants initially receive one of three standard immune checkpoint inhibitor-based regimens before randomization. After 10 to 14 weeks, eligible patients are randomly assigned to continue systemic immunotherapy with or without surgery to remove the kidney. Surgery may be performed within 8 weeks after randomization and can be done using laparoscopic, open, or robotic methods. Immunotherapies continue alongside axitinib unless surgery is planned, in which case axitinib is paused at least 24 hours before surgery. Throughout the study, participants undergo scans, physical exams, and laboratory tests to monitor tumor response and overall health. After treatment, patients are followed up every 3 months for the first year, then every 6 months for up to 3 years, and annually up to 7 years from randomization. The main measurement is overall survival, with additional assessments including tumor response, progression-free survival, treatment complications, and changes in tumor size at week 12. Specimens may be collected for future research.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Researchers are studying how certain factors like age, gender, other medical conditions, and the type of immunotherapy affect whether patients with malignant solid tumors develop mild or serious side effects from immune checkpoint inhibitor treatments. This observational study aims to develop and validate a model that predicts severe immune-related side effects during the first year of immunotherapy, while also assessing quality of life and adverse events over 12 months. The study is sponsored by the SWOG Cancer Research Network and includes translational medicine goals such as evaluating cytokine levels as predictors and establishing a tissue and blood sample repository. Participants will provide a tissue sample at the start of their routine cancer treatment and complete questionnaires at multiple time points at treatment start, and weeks 4, 12, 24, and 52. They may also provide optional blood samples during the study. This design allows researchers to monitor immune-related side effects and patient-reported outcomes over time. During the study, participants will complete various questionnaires to report their quality of life, cognitive function, and side effects. Blood and tissue samples will be analyzed to explore predictive markers of toxicity. Researchers will track the occurrence of severe immune-related side effects over 52 weeks and assess changes in patient-reported outcomes. The study includes ongoing monitoring and data collection, with participation lasting approximately one year from treatment start.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating EVO756, a medication taken orally, to study its effects on adults with migraine. This phase 2 trial aims to test the efficacy and safety of two different daily doses of EVO756 compared to a placebo. The study focuses on preventing migraines and is sponsored by Evommune, Inc. Participants will be randomly assigned to one of three groups one receiving daily Dose 1 of EVO756, another receiving daily Dose 2 of EVO756, or a placebo group taking a daily placebo pill. The treatment period lasts 12 weeks, during which participants take their assigned medication every day. Throughout the study, participants will have regular assessments to track changes in the number of monthly migraine and headache days, medication use, and any side effects. The main measurement is the change in monthly migraine days during the last month of treatment. Safety monitoring continues through week 16. The overall study runs from July 2026 to November 2027, with participants involved for at least 12 weeks of treatment and follow-up.
Actively Recruiting
Researchers are evaluating the addition of BMX-001, a manganese superoxide dismutase mimetic, to usual symptom management compared to usual symptom management alone to reduce oral mucositis in patients receiving chemoradiation for head and neck cancer. This phase II trial focuses on patients undergoing chemoradiation who often experience painful mouth sores and inflammation as side effects. BMX-001 aims to neutralize harmful substances and reduce damage to normal tissues during treatment. Participants are randomly assigned to one of two groups. Both groups receive cisplatin chemotherapy and intensity-modulated radiation therapy daily for 7 weeks per standard care. One group receives placebo injections, while the other group receives BMX-001 subcutaneously starting before radiation and cisplatin, then twice weekly for 8 weeks. Imaging with CT or MRI and optional blood sample collections are performed throughout the study. During the study, participants complete questionnaires and are monitored for oral mucositis severity, duration, and related symptoms like dry mouth and skin irritation. Follow-up visits occur at 1, 2, 3, 6, 12, and 24 months after treatment. Researchers also assess toxicity, survival outcomes, pain medication use, and collect samples for future research. The primary outcome is the incidence of severe oral mucositis from the start of radiation through 4 weeks after treatment completion.
Actively Recruiting
Researchers are evaluating the effect of chemotherapy drugs capecitabine and temozolomide after surgery in patients with high-risk well-differentiated pancreatic neuroendocrine tumors. This phase II trial compares treatment with these drugs to observation only, aiming to see if chemotherapy can prevent or delay cancer recurrence and improve survival. The study also assesses the safety and tolerability of this chemotherapy combination and collects specimens for future research. Participants are randomly assigned to one of two groups. In the first group, patients take capecitabine twice daily on days 1 to 14 and temozolomide once daily on days 10 to 14, repeating this 28-day cycle for up to 4 cycles if there is no disease progression or unacceptable side effects. The second group undergoes surveillance without active treatment. After treatment or observation, all patients are followed every 6 months for 3 years, then annually until 5 years from randomization. During the study, participants will have regular medical exams and scans to monitor for cancer recurrence or progression. Researchers will assess recurrence-free survival as the primary outcome over up to 5 years, with overall survival and side effects also tracked. Safety evaluations are done up to 30 days after treatment completion. This long-term follow-up helps understand how well patients do after surgery with or without chemotherapy.